Previous 10 | Next 10 |
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced two upcoming poster presentations at The Liv...
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live confe...
2023-09-27 01:43:08 ET Summary Atea Pharmaceuticals is a small biotech company with a focus on developing antiviral therapeutics for viral infections. Their lead product candidate, AT-527, is currently in a Phase III study for the treatment of COVID-19 in high-risk patients. A...
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea mana...
2023-08-17 17:37:41 ET Gainers: EDAP ( NASDAQ: EDAP ) +7% . Hyperfine ( HYPR ) +7% . Ross Stores ( ROST ) +6% . Verint Systems ( VRNT ) +6% . NanoString Technologies ( NSTG ) +4% . Losers: VinFast Auto ...
2023-08-10 10:20:13 ET More on Atea Atea Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Atea Pharmaceuticals, Inc. ( AVIR ) Q2 2023 Earnings Call Transcript Atea rejects takeover offer from Tang Capital Partners Atea Pharmaceuticals ...
2023-08-08 22:04:10 ET Atea Pharmaceuticals, Inc. (AVIR) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Jonae Barnes – Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi – Chi...
2023-08-08 17:49:56 ET Atea Pharmaceuticals press release ( NASDAQ: AVIR ): Q2 GAAP EPS of -$0.34 beats by $0.15 . Cash, Cash Equivalents and Marketable Securities: $608.1 million at June 30, 2023 compared to $646.7 million at December 31, 2022. ...
Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environment Enrollment continues in Phase...
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live confe...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...